TSO3 Inc has a 181 per cent upside, says Echelon Wealth

Jan 10 18:01 2019 Print This Article

Look for medical tech company TSO3 (TSO3 Stock Quote, Chart TSX:TOS) to become EBITDA-positive this year, says Echelon Wealth Partners analyst Douglas W. Loe, who in a client update on Wednesday reiterated his “Buy” rating and C$1.80 price target for TSO3, representing a projected return of 181 per cent at the time of publication. Loe […]

The post TSO3 Inc has a 181 per cent upside, says Echelon Wealth appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Startup jobs of the week: Canvass Analytics, Skritswap, Real Estate Webmasters

Every day, Canada’s tech startups post their latest and greatest job opportunities on Jobs.BetaKit, powered by Jobbio. From early-stage to Series B and beyond, Jobs.BetaKit helps startups from all over the country hire Canada’s top tech talent. Each week, BetaKit will highlight a selection of ...

How to Build “Old School” Wealth

If you’ve read my work, you probably know that my grandfather was my inspiration for getting into this business. He did well in the stock market, and his enthusiasm for investing rubbed off on me. My grandfather lived by his own homespun version of Peter Lynch’s advice to “buy what you kn ...

Hands-on with Microsoft HoloLens 2

Microsoft Corp. held a hands-on demo with several Canadian Journalists for the HoloLens 2 mixed-reality headset first revealed at MWC 2019 in Barcelona. What is HoloLens 2? Although it was initially marketed with consumer-oriented features, HoloLens 2 is still only available for enterprise. Because ...

The Week Ahead

The combination of the dovish hold by the Federal Reserve and the eurozone's miserable flash Purchasing Managers Index casts a pall over the economic outlook.  Japan's flash PMI remained stuck at February's 48.9, while core inflation unexpectedly eased.  Three months after the European Centr ...

OneSoft Solutions has an upside of 122 per cent, says Beacon Securities

Beacon Securities analyst Gabriel Leung has initiated coverage of pipeline data company OneSoft Solutions (OneSoft Solutions Stock Quote, Chart TSXV:OSS), saying that its subsidiary OneBridge Solutions is addressing a key risk in the oil and gas sector. Edmonton-based OneSoft operates a cloud-based ...

Sell Promis Neurosciences, Mackie Research says

An Alzheimer’s drug trial failure has caused Mackie Research analyst André Uddin to downgrade his rating for Promis Neurosciences (Promis Neurosciences Stock Quote, Chart TSX:PMN) from “Speculative Buy” to “Sell” in a client update on Thursday. A Phase III trial conducted by American bio ...

Cipher Pharma has a huge upside, says Echelon Wealth

Look for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH) to break out of its slump in 2019, says Doug Loe of Echelon Wealth Partners. Loe gives a 12-month return of 257 per cent for the stock, saying the specialty pharma company’s pipeline prospects are encouraging. Cip ...

Aurinia Pharma has a 56 per cent upside, Mackie Research says

Mackie Research analyst André Uddin is bullish on Canadian drug development company Aurinia Pharmaceuticals (Aurinia Pharmaceuticals Stock Quote, Chart NASDAQ:AUPH), whose calcineurin inhibitor drug voclosporin could reach global sales of more than $770 million in ten years time. BC-based Aurinia ...

Cipher Pharmaceuticals has a 155 per cent upside, Mackie Research says

Expect top line growth to reaccelerate for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH), says Mackie Research analyst André Uddin, who calls CPH a cheap pickup for investors. Canadian specialty pharma company Cipher released its fourth quarter and full year 2018 finan ...

Canadian Market Review 2019-03-15

The $TSX continues to inch higher week after week, suggesting that my caution in February was unwarranted. However, this week marks options expiration, as I mentioned early in the month. While the US market seems to find these dates important, the Canadian market finds them definitely importan ...